Abstract
As p53 and its homologue p73 have significant sequence and functional similarities, p73 might also be expected to act as a tumour suppressor. However, p73 is activated after DNA damage in a way that is distinct from that of p53. The existence of ΔNp73 - an isoform of p73 that is encoded by a distinct promoter and that lacks the transactivation domain - further complicates matters. It seems to function as an oncogene by inhibiting both p73- and p53-induced apoptosis. So how can these opposing functions be reconciled in human tumours?
| Original language | English |
|---|---|
| Pages (from-to) | 605-615 |
| Number of pages | 11 |
| Journal | Nature Reviews Cancer |
| Volume | 2 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2002 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
Cite this
p73 : Friend or foe in tumorigenesis. / Melino, Gerry; De Laurenzi, Vincenzo; Vousden, Karen H.
In: Nature Reviews Cancer, Vol. 2, No. 8, 08.2002, p. 605-615.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - p73
T2 - Friend or foe in tumorigenesis
AU - Melino, Gerry
AU - De Laurenzi, Vincenzo
AU - Vousden, Karen H.
PY - 2002/8
Y1 - 2002/8
N2 - As p53 and its homologue p73 have significant sequence and functional similarities, p73 might also be expected to act as a tumour suppressor. However, p73 is activated after DNA damage in a way that is distinct from that of p53. The existence of ΔNp73 - an isoform of p73 that is encoded by a distinct promoter and that lacks the transactivation domain - further complicates matters. It seems to function as an oncogene by inhibiting both p73- and p53-induced apoptosis. So how can these opposing functions be reconciled in human tumours?
AB - As p53 and its homologue p73 have significant sequence and functional similarities, p73 might also be expected to act as a tumour suppressor. However, p73 is activated after DNA damage in a way that is distinct from that of p53. The existence of ΔNp73 - an isoform of p73 that is encoded by a distinct promoter and that lacks the transactivation domain - further complicates matters. It seems to function as an oncogene by inhibiting both p73- and p53-induced apoptosis. So how can these opposing functions be reconciled in human tumours?
UR - http://www.scopus.com/inward/record.url?scp=0036674502&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036674502&partnerID=8YFLogxK
U2 - 10.1038/nrc861
DO - 10.1038/nrc861
M3 - Article
C2 - 12154353
AN - SCOPUS:0036674502
VL - 2
SP - 605
EP - 615
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
SN - 1474-175X
IS - 8
ER -